ALTEN Calsoft Labs, a leading Enterprise Digital Transformation solutions and Engineering R&D services company, has launched – “BioPharma Ledger”, a Blockchain clinical trial platform.
Clinlogix, a leading-edge global clinical research organization (CRO), with locations in Europe, Asia, South America and the US will be the first practitioner to pilot and implement the platform in real-world clinical trials.
JeanMarie Markham, the Founder and CEO of Clinlogix said:
“I’m very excited to be one of the first, if not the first, CRO who is moving ahead with the rapid development and deployment of a blockchain-based platform which will become an industry standard. Clinlogix has always embraced new technologies that improve patient outcomes, safety and health along with helping our sponsors to get new treatments to market rapidly, efficiently and cost-effectively. We are a decidedly different CRO and the new blockchain technology complements our ‘Innovation Pathway’ culture for all of our people and our customers.”
This reinforces ALTEN Calsoft Labs’ continued commitment to bringing Digital led transformation to industry-specific areas. The Blockchain practice provides customers with enterprise blockchain solutions in innovative business initiatives covering everything from business strategy and ideation to development and full enterprise scale. “The Blockchain for clinical trials is our first initiative in the broader Blockchain practice at ALTEN Calsoft Labs. We will make a significant impact on the clinical trial process with our scalable Blockchain platform that will ultimately address many key core processes in the Life Sciences industry. This will pave the way to fundamental changes in other key verticals that will demonstrate savings in costs, time and efficiency – all with the meaningful added benefits of security and trust,” says Paul Elisii, Vice President of BI and Blockchain, ALTEN Calsoft Labs.
“Blockchain will introduce us all to a new age of transparency, privacy and traceability in all aspects of the Life Sciences as we know them. It is as transformational to pharma, biotech and medical devices today, as the Internet was to communications 20 years ago. Blockchain has the power to fundamentally shift many core processes for drug research and development by increasing patient safety and privacy, improving quality of data, and significantly shortening the length of clinical trials,” says Nick Spring, Life Sciences Partner, ALTEN Calsoft Labs. “We are looking forward to working with the team at Clinlogix on this innovative approach.”
The newly created Blockchain Platform for clinical trials will leverage the BlockApps STRATO middleware platform. BlockApps is a founding member of the Enterprise Ethereum Alliance (EEA), the world’s largest open source blockchain initiative, and has the distinction as the first Blockchain platform available on Microsoft Azure, AWS, and Google Cloud.
ALTEN Calsoft Labs (ACL) is a digital transformation, next generation technology consulting and engineering services company. The Company offers Digital, Consulting, Enterprise IT and Product Engineering Services, in verticals like Retail, Healthcare, Life Sciences, Telecom, Manufacturing, Energy & Utilities, Networking, Semiconductor and High-Tech. ACL enables enterprises to Innovate, Integrate, and Transform their business by leveraging disruptive technologies like Blockchain, Digital Interactive, Cloud, Mobility, AI & RPA, Analytics, DevOps, IoT and Software-defined Networking (SDN/NFV).
- Clinlogix Joins ALTEN Calsoft in Launching Blockchain for Clinical Trials – July 3, 2019
- Binance Charity forms alliance with 46 companies to unveil a stablecoin for the alleviation of period poverty – July 3, 2019
- Nestlé Breaks from IBM Food Trust Blockchain Group for New Milk Supply Chain Trial – July 3, 2019
- Tokeny Solutions Digital Asset Platform Gets €5 Million Backing from Euronext – July 3, 2019
- Blockchain Venture Capital Funding Reaches $822 Million in 2019 – July 1, 2019
- Toronto’s Creative Destruction Lab Joins Facebook’s Libra Association – June 19, 2019
- Australia’s Power Ledger to bring P2P Energy Trading to Austria – June 19, 2019
- Litecoin Foundation Teams Up With Bibox And Ternio On Special Edition Litecoin Debitcard – June 19, 2019
- US Legislators Call for Halt to Facebook’s Cryptocurrency Plans – And to Face Congress – June 19, 2019
- Hyperledger Welcomes Diverse Line-up of New Members for Identity Project – June 18, 2019
- Facebook Announces Calibra Digital Wallet and Libra Cryptocurrency – June 18, 2019
- MIT Professor Silvio Micali’s Algorand Project Announces Date for First Auction – June 6, 2019
- SEC sues Canadian Messaging Service Kik Selling Unregistered Securities in its $100 million ICO – June 4, 2019
- CrowdEngine Teams Up With Polymath Adding Security Token Issuance to List of Crowdfunding Services – June 3, 2019
- Bitcoin Inc. CEO Morgan Rockcoon Busted – 21 Months in Prison and Fines – June 3, 2019
- Reshaping a Nation’s Logistics Sector: Singaporean Blockchain Company PLMP Cuts Multimillion Dollar Deal With Indonesia – June 3, 2019
- Swisscom TV Opens Blockchain-based Art Gallery – June 3, 2019
- Canadian Messaging Service Kik Burns $5 Million Fighting SEC Over Utility Tokens, Now Raising $5 Million More to Continue Battle – June 3, 2019
- Salesforce Introduces CRM Blockchain Platform For Selected Clients – June 3, 2019
- Block.one Plans to Tackle Pitfalls of Social Media With New Blockchain Community Called “Voice” – June 3, 2019
Also published on Medium.
Worldwide use of robotic process automation has led to significant, positive impacts on business productivity. In 2018 the adoption of robotic process automation grew globally at a higher pace than ever before. Extrapolating RPA’s growth trajectory into the near future would imply adoption as a necessary step that competitive businesses must take. According to the Institute for Robotic Process Automation and Artificial Intelligence Survey from June 2018, 66% of respondents were considering expansion of robotic process automation programs and 70% were allocating increased funds for investment in 2019.